Core Viewpoint - Silver诺医药-B's stock surged over 17% following the announcement of its clinical trial application for a new veterinary drug aimed at treating diabetes in pets, which has been officially accepted by the Ministry of Agriculture and Rural Affairs of China [1] Group 1: Company Developments - The company announced that its core product, Isu-Paglutide α, is set to enter Phase I clinical trials for treating pet diabetes, expected to commence in the first quarter of 2026 [1] - The board believes that developing diabetes medication for pets presents significant market potential, as pet owners are increasingly willing to invest in extending their pets' lifespans [1] - The company has complied with all regulatory standards and successfully completed the necessary preclinical trials, showing positive results in efficacy and safety for managing diabetes in pets [1]
港股异动 | 银诺医药-B(02591)早盘拉升逾17% 依苏帕格鲁肽α在宠物糖尿病管理已取得积极进展